We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Compugen Ltd | NASDAQ:CGEN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -1.05% | 1.89 | 1.85 | 1.89 | 1.94 | 1.84 | 1.94 | 392,094 | 22:50:31 |
From Jul 2019 to Jul 2024
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the fourth quarter and year-ending December 31, 2010.
Dr. Anat Cohen-Dayag, president and CEO, stated, “Compugen’s long-term commitment to pioneering predictive drug discovery continues to provide the basis for the development of unique and powerful discovery capabilities in areas of high industry interest and unmet medical needs. For example, during 2010 we announced the development of three additional discovery platforms: the Protein Family Members Discovery Platform, the Protein-Protein Interaction Blockers Discovery Platform, and the Intracellular Drug Delivery Discovery Platform. In addition, during the past few months, field extension modules were added to our previously disclosed monoclonal antibody (mAb) target discovery capability.”
Dr. Cohen-Dayag continued, “Antibody therapeutics comprise the fastest growing drug field and are now yielding improved therapeutics to treat many life-threatening and debilitating diseases. Although significant progress has been made in recent years, one of the key challenges in the mAb therapeutic field remains the identification and validation of novel targets that are overexpressed in a particular disease state or involved in the modulation of the disease. Such targets allow the development of antibody-based therapeutic molecules which can either specifically destroy these cells - while sparing normal and healthy tissues - or modulate the course of the disease.”
Dr. Cohen-Dayag continued, “With the recently added field extension modules, Compugen’s mAb target discovery capability has been expanded beyond the initial focus on various solid tumors such as lung, ovarian, breast, colorectal and hematological cancers, which had resulted in the discovery of a number of drug target candidates for antibody-based therapy, including the previously disclosed CGEN-928, a drug target candidate for treatment of multiple myeloma, and CGEN-671, a drug target candidate for treatment of epithelial cancers. The new capabilities are now enabling the discovery of drug targets involved in drug response, metastatic stage cancer, and additional cancers such as melanoma, renal, liver, and pancreatic. Utilizing these new modules, we have already added five additional product candidates to our Pipeline Program, bringing the current total to more than 30 candidate protein therapeutics, peptide therapeutics and targets for mAb therapy at various stages of validation. With respect to the overall Pipeline Program, we are extremely pleased by our progress to date and look forward to disclosing additional information regarding specific molecules during the coming months.”
As previously stated, since current revenues result primarily from fees and milestones, our results are, and will continue to be, subject to substantial fluctuations due to timing. Revenues for the fourth quarter of 2010 were $190,000 compared with $25,000 for the comparable period of 2009, and revenues for calendar 2010 were $1.1 million compared with $250,000 for calendar 2009.
The net loss for the most recent quarter was $2.0 million (including a non-cash expense of $343,000 related to stock based compensation), or $0.06 per share, compared with a net loss of $2.0 million (including a non-cash expense of $440,000 related to stock based compensation), or $0.07 per share, for the corresponding quarter of 2009. The net loss for calendar 2010 was $7.2 million (including a non-cash expense of $2.1 million related to stock based compensation), or $0.22 per share, compared with a net loss of $3.8 million (including a non-cash expense of $1.5 million related to stock based compensation), or $0.13 per share, for 2009.
The increase in net loss for calendar 2010 compared with calendar 2009 is due to the sale by Compugen during the second quarter of 2009 of a portion of its holdings of Evogene Ltd. shares for a gain of approximately $3.6 million, which is included in “Other income” for 2009.
Research and development expenses for the fourth quarter of 2010 were $1.8 million, compared with $1.6 million for the fourth quarter of 2009 and remained the Company’s largest expense. Research and development expenses for calendar 2010 were $6.2 million compared with $6.0 million for 2009. These amounts are before the deduction of governmental and other grants, which totaled $205,000 for the fourth quarter of 2010, compared with $247,000 for the corresponding quarter in 2009, and $1.0 million for calendar 2010, compared with $944,000 for 2009.
At year-end 2010, the asset “Receivables from financing arrangement” in the amount of $5.0 million (which was subsequently collected by the Company in full in early 2011) and the liability “Research and development funding arrangement” in the amount of $4.0 million both relate to the research and development funding arrangement signed in December of 2010. The $4.0 million liability is an estimated value of the instrument for accounting purposes resulting from the right of the investor to waive his right to receive potential future payments in exchange for 833,334 Compugen ordinary shares.
As of December 31, 2010, cash and cash related accounts totaled $21.8 million compared with $23.4 million at December 31, 2009 (including for 2009 remaining receivables from the equity offering completed in late December 2009). These amounts do not include either the market value of Compugen’s holdings of Evogene shares at each such year-end, or for 2010, the $5.0 million received in early 2011 from a research and development funding arrangement signed prior to year-end 2010 referred to in the prior paragraph. For calendar 2011, the Company anticipates an increase in gross cash expenditures to approximately $10 million due primarily to increased activities under its expanded Pipeline Program. Such estimated gross cash expenditures will be offset by revenues and other cash sources in calculating net cash flow for the year.
Conference Call and Webcast Information
Compugen will hold a conference call to discuss its fourth quarter and year-end results on Tuesday, February 15, 2011 at 10:00 a.m. EST. To access the conference call, please dial 1-888-407-2553 from the US or 972-3-918-0610 internationally. The call will also be available via live webcast through Compugen’s website, located at the following link.
A replay of the conference call will be available approximately two hours after the completion of the live conference call. To access the replay, please dial 1-888-295-2634 from the US or 972-3-925-5921 internationally. The replay will be available until 12 noon EST on February 18, 2011.
About Compugen
Compugen is a leading drug and diagnostic product candidate discovery company. Unlike traditional high throughput trial and error experimental based discovery, Compugen's discovery efforts are based on in silico (by computer) product candidate prediction and selection utilizing a broad and continuously growing infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology tools to address important unmet therapeutic and diagnostic needs – both for Compugen and its partners. Compugen's growing number of collaborations covering the further development and commercialization of Compugen-discovered product candidates provides Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. These collaborations may be entered into before product candidate discovery is undertaken pursuant to "discovery on demand" type arrangements, or with respect to existing product candidates, collaborations can be initiated prior to or at the proof of concept stage, or after additional preclinical activities have been undertaken by Compugen. In 2002, Compugen established an affiliate, Evogene Ltd. (www.evogene.com) (TASE: EVGN.TA), to utilize certain of the Company's in silico predictive discovery capabilities in agricultural biotechnology. For additional information, please visit Compugen's corporate website at www.cgen.com.
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may", "expects", "anticipates", "believes", and "intends", and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are identified and more fully explained under the heading "Risk Factors" in Compugen's annual reports filed with the Securities and Exchange Commission.
COMPUGEN LTD.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except for share and per-share amounts)
Three Months EndedDecember 31,
Year Ended December 31,
2010 2009 2010 2009 Revenues 190 25 1,115 250 Cost of revenues 26 - 224 -
Gross profit
164 25 891 250 Research and development expenses 1,757 1,625 6,237 5,995 Less: governmental and other grants (205) (247) (1,010) (944) Research and development expenses, net 1,552 1,378 5,227 5,051 Marketing and business development expenses 98 21 633 681 General and administrative expenses 814 577 2,909 2,147Total operating expenses *
2,464 1,976 8,769 7,879 Operating loss (2,300) (1,951) (7,878) (7,629) Financing income (loss), net (111) (152) 241 65 Other income 397 64 434 3,721 Net loss from continuing operations (2,014) (2,039) (7,203) (3,843) Gain (loss) from discontinued operations - (2) - 12 Net loss (2,014) (2,041) (7,203) (3,831) Basic and diluted loss per ordinary share from continuing operations (0.06) (0.07) (0.22) (0.13) Basic and diluted loss per ordinary share from discontinued operations - - - - Basic and diluted net loss per ordinary share (0.06) (0.07) (0.22) (0.13) Weighted average number of ordinary shares outstanding 33,536,120 28,852,335 33,284,017 28,608,317* Includes stock based compensation
COMPUGEN LTD.
CONDENSED CONSOLIDATED BALANCE SHEETS DATA
(U.S. dollars, in thousands)
December 31,2010
December 31,2009
ASSETS Current assets Cash, cash equivalents and short-term bank deposits 21,824 15,639 Restricted cash 684 161 Trade receivables 21 - Accounts receivables and prepaid expenses 548 720 Receivables from financing arrangements 5,000 7,790 Total current assets 28,077 24,310 Long-term investments Investment in Evogene 6,227 3,898 Long-term prepaid expenses 64 18 Severance pay fund 1,510 1,224 Total long-term investments 7,801 5,140 Property and equipment, net 580 735 Total assets 36,458 30,185 LIABILITIES AND SHAREHOLDERS’ EQUITY Current liabilities Accounts payable and accrued expenses 2,441 1,357 Deferred revenues - 113 Total current liabilities 2,441 1,470 Long-term liabilities Research and development funding arrangement 4,037 - Accrued severance pay 1,695 1,317 Total long-term liabilities 5,732 1,317 Total shareholders’ equity 28,285 27,398 Total liabilities and shareholders’ equity 36,458 30,185
1 Year Compugen Chart |
1 Month Compugen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
